ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0865

Application of a Prognostic Prediction Model in IgAN in the Brazilian Population

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Luciano, Eduardo De paiva, Universidade Federal de Sao Paulo Escola Paulista de Medicina, São Paulo, SP, Brazil
  • Mastroianni-Kirsztajn, Gianna, Universidade Federal de Sao Paulo Escola Paulista de Medicina, São Paulo, SP, Brazil
Background

IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide and a leading cause of chronic kidney disease (CKD). A major challenge in monitoring IgAN is its highly heterogeneous risk of progression, with 10-year progression to end-stage CKD ranging from 5% to 60%. Although risk stratification is recommended to guide immunosuppressive therapy, no tool was previously available to accurately predict CKD progression. To address this, an international IgAN-specific risk calculator was developed and validated. This study aimed to apply this tool to define renal prognosis in Brazilian patients with IgAN, identifying a cutoff associated with higher risk for adverse renal outcomes.

Methods

This observational, retrospective, single-center study included 131 adult patients with biopsy-proven IgAN, followed at the glomerulonephritis outpatient clinic at UNIFESP/EPM between 2005 and 2015, with at least 5 years of follow-up. The international IgAN risk calculator was applied to each patient. The primary composite outcome was end-stage CKD (eGFR <15 ml/min, initiation of renal replacement therapy, or kidney transplantation) and/or a 50% decline in eGFR within 60 months post-biopsy.

Results

Among 131 patients, 57.3% were male, mean age 46.5 years, mean follow-up 133.6 months; 61.8% were white. Mean eGFR at biopsy was 64.9 ± 21.3 ml/min; proteinuria was 2.53 ± 1.84 g/day. Outcomes occurred in 29.8% (n=39). Higher calculated risk correlated with greater prevalence of outcomes. A cutoff point of 22.78% optimally differentiated low/moderate from high/very high risk for adverse renal outcomes. The risk of a 50% eGFR decline was 49.2 times higher when the calculator result exceeded 27.78% (OR=49.2, 95% CI: 15.9–152.6). Renal survival was significantly better in patients with proteinuria <1 g/day (p=0.001), and dialysis-free survival was higher among those with eGFR >60 ml/min (p=0.028).

Conclusion

Application of the international IgAN risk calculator effectively stratified Brazilian patients, independent of race. A robust cutoff point was identified to distinguish low from high-risk individuals for progression to end-stage CKD.

Digital Object Identifier (DOI)